Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Susanna B. Park,David Goldstein,Arun V. Krishnan,Cindy S.-Y. Lin,Michael Friedlander,James T. Cassidy,Martin Koltzenburg,Matthew C. Kiernan +7 more
Reads0
Chats0
TLDR
This review will address the increasing importance and challenge of chemotherapy‐induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers.Abstract:
With a 3-fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of long-term toxicities and the impact on quality of life following treatment in cancer survivors. This review will address the increasing importance and challenge of chemotherapy-induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers. An overview of the diagnosis, symptomatology, and pathophysiology of chemotherapy-induced peripheral neuropathy will be provided, with a critical analysis of assessment strategies, neuroprotective approaches, and potential treatments. The review will concentrate on neuropathy associated with taxanes, platinum compounds, vinca alkaloids, thalidomide, and bortezomib, providing clinical information specific to these chemotherapies. CA Cancer J Clin 2013;63:419-437. ©2013 American Cancer Society, Inc.read more
Citations
More filters
Journal ArticleDOI
Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
Mark K. Greenwald,Julie J. Ruterbusch,Jennifer L. Beebe-Dimmer,Michael S. Simon,Terrance L. Albrecht,Ann G. Schwartz +5 more
TL;DR: An epidemiological analysis identifies risk factors for the incidence of CIPN and identifies factors that modulate the development and clinical impact of the disease.
Journal ArticleDOI
Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review
Hannah C. Timmins,David Mizrahi,Tiffany Li,Matthew C. Kiernan,Matthew C. Kiernan,David Goldstein,Susanna B. Park +6 more
TL;DR: In this paper, a systematic review aimed to investigate the association between common metabolic-lifestyle factors and CIPN, and found that obesity had the most consistent patient-oriented evidence as a risk factor for CIPNs.
Journal ArticleDOI
Treatment Intensity Differences After Early-Stage Breast Cancer (ESBC) Diagnosis Depending on Participation in a Screening Program.
Kenneth Elder,Carolyn Nickson,Carolyn Nickson,Melinda Pattanasri,Samuel Cooke,Dorothy A Machalek,Allison Rose,Arlene Mou,John P. Collins,John P. Collins,Allan Park,Richard De Boer,Claire Phillips,Vicki Pridmore,Helen Farrugia,G. Bruce Mann,G. Bruce Mann +16 more
TL;DR: Differences persist when potential overdiagnosis is taken into account; these differences should be factored into debates around mammographic screening.
Journal ArticleDOI
In vitro assessment of chemotherapy-induced neuronal toxicity
Chelsea Snyder,Lanlan Yu,Tin Ngo,Daniel Sheinson,Yuda Zhu,Min Tseng,Dinah Misner,Karin Staflin +7 more
TL;DR: A novel approach to assess neurotoxicity caused by different classes of chemotherapeutics is described using kinetic monitoring of neurite dynamic changes and apoptosis in human iPSC-neurons, showing promising changes in neurite dynamics in response to clinical inducers of neuropathy.
Journal ArticleDOI
Therapeutic Effects of Phytochemicals and Medicinal Herbs on Chemotherapy-Induced Peripheral Neuropathy
Gihyun Lee,Sun Kwang Kim +1 more
TL;DR: Current knowledge regarding the role of phytochemicals, herb extracts, and herbal formulas in alleviating CIPN is summarized.
References
More filters
Journal ArticleDOI
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
A. de Gramont,A. Figer,M. Seymour,M. Homerin,A. Hmissi,J. Cassidy,Corrado Boni,H. Cortes-Funes,Andrés Cervantes,Gilles Freyer,Demetris Papamichael,N. Le Bail,C. Louvet,D. Hendler,F. de Braud,C. Wilson,Francois Morvan,Andrea Bonetti +17 more
TL;DR: The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
Journal ArticleDOI
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André,Corrado Boni,Lamia Mounedji-Boudiaf,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Marta Zaninelli,Phillip Clingan,John Bridgewater,Isabelle Tabah-Fisch,Aimery de Gramont +11 more
TL;DR: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Journal ArticleDOI
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
Andy Trotti,A. Dimitrios Colevas,Ann Setser,Valerie W. Rusch,David P. Jaques,Volker Budach,Corey J. Langer,Barbara A. Murphy,Richard Cumberlin,C. Norman Coleman,Philip Rubin +10 more
TL;DR: Recent progress in the evolution of adverse effects grading systems is updated and the development of CTCAE v3.0 is reviewed, which represents an international collaboration and consensus of the oncology research community.
Journal ArticleDOI
Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values
Roman Rolke,Ralf Baron,Christoph Maier,Thomas R. Tölle,Rolf-Detlef Treede,Antje Beyer,Andreas Binder,Niels Birbaumer,Frank Birklein,I. C. Bötefür,S. Braune,Herta Flor,Volker Huge,R. Klug,G. B. Landwehrmeyer,Walter Magerl,Christian Maihöfner,C. Rolko,C. Schaub,Andrea Scherens,Till Sprenger,Michael Valet,B. Wasserka +22 more
TL;DR: Application of this standardized QST protocol in patients and human surrogate models will allow to infer underlying mechanisms from somatosensory phenotypes as well as judge plus or minus signs in patients.
Related Papers (5)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more